2026-01-02 - Analysis Report
Here's a comprehensive analysis of Schrodinger Inc. (SDGR) based on the provided data:

**0) Overall Performance & Comparison**

*   **SDGR Cumulative Return:** -55.41%
*   **VOO (S&P 500) Cumulative Return:** 69.47%
*   **Divergence:** -124.9 (Relative Divergence: 1.3)

**1) Comparison with S&P 500 (VOO)**

*   **Company Overview:** Schrodinger Inc. is a company focused on developing software for drug discovery and materials science.
*   **Analysis:** SDGR has significantly underperformed the S&P 500, with a large negative divergence. A relative divergence of 1.3 suggests that current divergence is positioned near the minimum divergence observed in the past.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha   | Beta | Cap(B) |
|------------|----------|---------|---------|------|--------|
| 2021-2023  | -60.0%   | 84.7%   | -89.0%  | 1.8  | 2.6    |
| 2022-2024  | -32.0%   | 81.0%   | -62.0%  | 1.8  | 1.4    |
| 2023-2025  | -26.0%   | 85.6%   | -94.0%  | 1.8  | 1.3    |

*   **CAGR:** Negative Compound Annual Growth Rate indicates poor performance over the given periods.
*   **MDD:** High Maximum Drawdown figures suggest significant volatility and risk.
*   **Alpha:** Highly negative Alpha suggests that the stock has consistently underperformed relative to its benchmark (likely the S&P 500), meaning it's not generating excess returns.
*   **Beta:** A Beta of 1.8 indicates that SDGR's price is significantly more volatile than the overall market.
*   **Cap(B):** The company's market capitalization is decreasing.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $17.88
*   **Previous Close:** $17.8
*   **Change:** 0.45
*   **5-day SMA:** 18.042
*   **20-day SMA:** 18.0135
*   **60-day SMA:** 18.8147

*   **Analysis:** The stock price is currently slightly above its previous close. The 5-day and 20-day SMAs are relatively close, suggesting a period of price consolidation. The 60-day SMA is higher, indicating a longer-term downward trend.

**3) Indicators & Signals**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment)
*   **RSI:** 49.43 (Neutral)
*   **PPO:** 0.1821 (Neutral)
*   **Hybrid Signal:** 100% Buy (Based on MRI 0.9)
*   **Recent (20 days) Relative Divergence Change:** -0.4 (Short-term decline)
*   **Expected Return (%):** 0.0% (No expected excess return compared to S&P 500)

*   **Analysis:** While the MRI suggests a medium investment recommendation, the RSI and PPO indicators are neutral. The Hybrid Signal is giving a "Buy" recommendation, based solely on the MRI. The recent decline in relative divergence is a negative signal. The expected return of 0.0% is concerning for a long-term investment. Fluctuation in price indicates some positive news.

**4) Recent News & Significant Events**

*   **Positive Headlines:** "Great 'Buy the Bottom' Stock Now," "New Analyst Forecast: $24 Price Target," "Shares Purchased by Nikko Asset Management."
*   **Other Headlines:** "Unlocking Hidden Value," Morgan Stanley Initiates Coverage.

*   **Analysis:** Recent news is mixed. Some articles suggest a potential buying opportunity, while others focus on analyst price targets and institutional investment. It's important to note that even articles suggesting a "Buy the Bottom" opportunity acknowledge the poor historical performance.

**4-2) Analyst Opinions**

*   **Mean Target Price:** $27.22 (suggests significant upside)
*   **High Target Price:** $33.00
*   **Low Target Price:** $18.00

*   **Analysis:** The average analyst target price suggests substantial upside potential, but there is a wide range of opinions, indicating uncertainty about the company's future. The lack of recent rating changes may mean that analysts are waiting for further data before updating their ratings.

**5) Recent Earnings Analysis**

| 날짜       | EPS     | 매출      |
|------------|---------|-----------|
| 2025-11-05 | -0.45   | 0.05 B$   |
| 2025-08-06 | -0.59   | 0.05 B$   |
| 2025-05-07 | -0.82   | 0.06 B$   |
| 2024-11-12 | -0.52   | 0.04 B$   |
| 2025-11-05 | -0.52   | 0.04 B$   |

*   **Analysis:** Schrodinger has consistently reported negative EPS, indicating unprofitability. While revenue has fluctuated, it hasn't been enough to offset losses.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.05B   | 51.61%        |
| 2025-06-30 | $0.05B   | 47.77%        |
| 2025-03-31 | $0.06B   | 52.26%        |
| 2024-12-31 | $0.09B   | 72.61%        |
| 2024-09-30 | $0.04B   | 50.24%        |

*   **Analysis:** Revenue is inconsistent, and while profit margins are high, they are not high enough to generate overall profitability given the current revenue levels. The revenue figure of 2024-12-31 stands out.

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-09-30 | $0.32B   | -10.21%   |
| 2025-06-30 | $0.34B   | -12.59%   |
| 2025-03-31 | $0.37B   | -16.01%   |
| 2024-12-31 | $0.42B   | -9.54%    |
| 2024-09-30 | $0.45B   | -8.49%    |

*   **Analysis:** Equity is decreasing, which is generally not a positive sign. Negative ROE (Return on Equity) confirms that the company is not generating profits from its equity.

**7) Comprehensive Analysis (Summary)**

Schrodinger Inc. (SDGR) has significantly underperformed the S&P 500, experiencing a large negative divergence. Its financial performance has been weak, with consistent losses, declining equity, and negative ROE. Recent news is mixed, with some suggesting a potential buying opportunity but also acknowledging significant risk. Analyst target prices suggest substantial upside, but there is a wide range of opinions. The technical indicators are neutral to slightly negative.

**Overall Recommendation:**

Based on the provided data, an investment in SDGR is highly risky. While some analysts see upside potential, the company's financial performance, negative historical returns, and high volatility suggest caution. The MRI suggests a medium investment, but it should be weighted against the considerable evidence to the contrary. Potential investors should carefully consider their risk tolerance and conduct further due diligence before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.